Davita Inc (NYSE:DVA) saw some unusual options trading on Wednesday. Stock investors purchased 5,852 put options on the stock. This represents an increase of 2,289% compared to the typical volume of 245 put options.
In other news, Director Pamela M. Arway sold 1,264 shares of the stock in a transaction dated Thursday, June 7th. The stock was sold at an average price of $68.76, for a total value of $86,912.64. Following the transaction, the director now owns 39,235 shares in the company, valued at approximately $2,697,798.60. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director William L. Roper sold 1,505 shares of the firm’s stock in a transaction that occurred on Tuesday, May 22nd. The stock was sold at an average price of $68.22, for a total value of $102,671.10. Following the transaction, the director now owns 46,733 shares in the company, valued at approximately $3,188,125.26. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 3,107 shares of company stock valued at $211,976. 0.95% of the stock is owned by company insiders.
Large investors have recently added to or reduced their stakes in the stock. Captrust Financial Advisors bought a new position in shares of Davita during the fourth quarter valued at approximately $113,000. NuWave Investment Management LLC bought a new position in Davita in the 1st quarter worth approximately $173,000. Green Square Capital LLC bought a new position in Davita in the 4th quarter worth approximately $217,000. Kovitz Investment Group Partners LLC bought a new position in Davita in the 4th quarter worth approximately $221,000. Finally, IBM Retirement Fund acquired a new stake in Davita in the first quarter worth approximately $212,000. Institutional investors and hedge funds own 87.67% of the company’s stock.
Davita (NYSE:DVA) last issued its quarterly earnings data on Thursday, May 3rd. The company reported $1.05 EPS for the quarter, topping the Zacks’ consensus estimate of $0.92 by $0.13. The company had revenue of $2.85 billion for the quarter, compared to analysts’ expectations of $2.79 billion. Davita had a return on equity of 13.84% and a net margin of 2.94%. The firm’s quarterly revenue was up 8.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.79 earnings per share. research analysts anticipate that Davita will post 4.09 earnings per share for the current year.
Separately, William Blair reissued a “buy” rating on shares of Davita in a report on Wednesday, June 6th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, five have given a buy rating and two have given a strong buy rating to the company’s stock. Davita currently has a consensus rating of “Buy” and an average price target of $81.22.
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.